Botox approved for migraine prevention

Botox is already licensed for use in certain types of muscle spasm and spasticity, as well as severe axillary hyperhidrosis
Botox is already licensed for use in certain types of muscle spasm and spasticity, as well as severe axillary hyperhidrosis

Botox (botulinum toxin type A) is the first agent to be specifically indicated for the prevention of chronic migraine. It is indicated for use only in adults who have headaches on at least 15 days per month, of which eight days or more are with migraine.

Pooled analysis of two trials in a total of 1384 patients (PREEMPT 1 and 2) showed that botulinum toxin A was more effective than placebo at reducing the incidence of days affected by headache. During 24 weeks of double-blind treatment, the mean number of headache days per month fell by 8.4 in the toxin group compared with 6.6 in the placebo group (p<0.001).

The treatment is administered as a series of 31 to 39 intramuscular injections every 12 weeks, across seven head/neck muscle areas. The injections must be performed by a specialist.

The toxin is thought to suppress peripheral pain signals to the central nervous system by blocking the release of neurotransmitters.

View Botox drug record

Further information: Allergan

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Topical Steroids, Comparison of Potencies and Formulations

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Topical Steroids, Potential Skin Sensitisers as Ingredients

Topical Steroids, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in topical steroids.

Correct vitamin D deficiency to reduce COPD exacerbations, say researchers

Correct vitamin D deficiency to reduce COPD exacerbations, say researchers

Vitamin D supplements could nearly halve the rate of...

Launch of new SGLT2 inhibitor increases choice in diabetes prescribing

Launch of new SGLT2 inhibitor increases choice in diabetes prescribing

Ertugliflozin (Steglatro) is a sodium glucose co-transporter...